Bear, you certainly are comprehensive.  I would like to add the following -

I think Don was smiling because he had a win/win situation.  He has eliminated the slow enrolling sites and replaced them with potentially fast US enrolling sites.  At the same time, the faster world sites are still completing enrollment.  If the US can enroll 10% or 240 patients, then say 12 sites could enroll 20 patients each.  US enroll could be completed in say 4 months, with resulting say 6 to 8 month US trial length by the end of 2018.  Final evaluation could commence at the start of 2019.  Final US enrollment might occur at the same time as the FA in say 4 months, and the 188 could project to 250 by year end.  Perhaps you are better at calculations and projections than I am.

The real reason that Don should be smiling is that our arm of the study is now being tested (as firmly required by the FDA) against both of the popular statins on the market including the generics.  A sucessfull completion of a phase 3 trial will prove that the RVX formulation is better than all existing statins currently available.  Quite a market domination :) Don

JMHO

Absolutely